Personalized mRNA melanoma vaccine with Keytruda shows Phase 3 promise
TL;DR Summary
Merck and Moderna reported that a personalized neoantigen mRNA vaccine, intismeran, added to Merck's Keytruda in adjuvant melanoma slowed recurrence and metastasis in a Phase 3 trial, signaling a potential new class of cancer immunotherapies, though detailed data have yet to be released.
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STAT
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial CNBC
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano Yahoo Finance
- Moderna-Merck MRNA Shot Helped Cut Melanoma Recurrence in Big Trial Bloomberg.com
- Cancer treatment could face landmark moment with promising vaccine The Washington Post
Reading Insights
Total Reads
1
Unique Readers
6
Time Saved
2 min
vs 3 min read
Condensed
91%
482 → 43 words
Want the full story? Read the original article
Read on STAT